EYEG - EyeGate Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4464
-0.0036 (-0.80%)
As of 2:16PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.4500
Open0.4348
Bid0.442 x 800
Ask0.450 x 800
Day's Range0.4348 - 0.4520
52 Week Range0.2750 - 0.8600
Volume44,425
Avg. Volume283,830
Market Cap19.393M
Beta (3Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)-0.385
Earnings DateFeb 28, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • GlobeNewswire22 days ago

    EyeGate Pharmaceuticals to Present at BIO CEO & Investor Conference in New York City

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”) today announced that the Company will attend and present at the 21st BIO CEO & Investor Conference being held in New York, NY at the New York Marriott Marquis on February 11th & 12th, 2019. The Company will also host one-on-one meetings through BIO CEO & Investor conference, which is one of the largest, unbiased forums of institutional investors, industry analysts, and biotechnology executives. Conference attendees can request meetings through the One-on-One Partnering platform, while non-attendees can send meeting requests to Joe Green at Edison Advisors.

  • GlobeNewswirelast month

    EyeGate Pharmaceuticals Announces Meeting Date with FDA

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”) today confirmed that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on Wednesday, March 20th, 2019 to discuss EyeGate’s de novo application strategy for its Ocular Bandage Gel (OBG) product, which will cover the clinical plan, data to date, and potential submission timelines. EyeGate’s OBG platform, a unique cross-linked hyaluronic acid compound, has potentially broad applications in managing ocular surface damage due to a variety of conditions, ranging from punctate epitheliopathies (PE) commonly found in dry eye patients, to large epithelial defects like those that occur following photorefractive keratectomy (PRK). EyeGate’s OBG platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S), a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface.

  • Zacks Small Cap Research3 months ago

    EYEG: Is EyeGate Eyeing FDA Filings Following Positive OBG Data in Both PRK and PE?

    EyeGate (EYEG) announced Q3 financial results and provided a business update. To-date, EYEG has received $13.8M in upfront and milestones under the two agreements, including ~$300k in the most recent quarter. While the yoy decrease reflects a change in activity from the relatively large EGP-437 trials to the smaller OBG studies, the qoq increase is a result of continued progression of both OBG programs.

  • ACCESSWIRE3 months ago

    Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity

    HENDERSON, NV / ACCESSWIRE / November 14, 2018 / With the sharp declines in biotechnology stocks, with the iShares Nasdaq Biotechnology exchange traded fund (ETF) and SPDR S&P Biotech ETF recently down ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Viking Therapeutics and EyeGate Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Shares of EyeGate exploded on Tuesday on tremendous volume after reporting third quarter financial results. Shares of Viking Therapeutics were little changed ...

  • ACCESSWIRE3 months ago

    4 Healthcare Stocks Investors Are Watching In November

    Eighty-three percent of healthcare organizations responding to an American Telemedicine Association* poll said they are highly likely to invest in telehealth with operational efficiency and convenience in mind. Of the 171 healthcare executives participating in the annual ATA Executive Leadership Survey, 88% of those who are likely to purchase telehealth tools are planning to do so. "This executive leadership survey confirms undeniably today's leaders view telemedicine as a major driver in transforming healthcare," said Jonathan Linkous, CEO, American Telemedicine Association.

  • Zacks Small Cap Research5 months ago

    EYEG: Focus Is On OBG As U.S. Pilot Studies Fully Enrolled. Data Expected Q4. EGP-437 Ph3 AE Data Disappoints

    EyeGate (EYEG) reported Q2 2018 financial results and provided a business update. Through Q2, EYEG collected $13.5M from Valeant related to upfront payments and development milestones associated with the development agreements for EGP-437 in anterior uveitis and post-cataract surgery. In terms of how these payments are recognized on EYEG’s financial statements, as a reminder an updated FASB standard governing revenue-recognition for contracts with customers resulted in a $9.5M adjustment to EYEG’s deferred revenue balance (as of Jan 1, 2018) – this is solely an accounting adjustment with no cash effect.

  • Zacks Small Cap Research7 months ago

    EYEG: IDEs Approved. Both OBG Clinical Studies Set to Kick-Off

    As we noted in our Q1 ’18 earnings update in late-May, Eyegate Pharmaceuticals' (EYEG) diligence in rapidly responding to FDAs follow-on questions related to their IDE submission has been key to keeping their Ocular Bandage Gel (OBG) programs on-track with updated forecasted timelines. EYEG had previously been guiding for commencement of both studies during Q3 (i.e.

  • EyeGate Pharmaceuticals Stock Rose ~5.8% on July 24
    Market Realist7 months ago

    EyeGate Pharmaceuticals Stock Rose ~5.8% on July 24

    On July 24, EyeGate Pharmaceuticals (EYEG) announced that it has secured FDA approval for two investigational device exemption applications related to pilot studies for the company’s OBG (ocular bandage gel) product scheduled to commence in the third quarter. In one pivotal study, the company will compare the OBG (or CHMA-S) product with the combination of bandage contact lens and artificial tears, which is the current standard of care for patients who have undergone photorefractive keratectom and require accelerated re-epithelialization of the corneal wounds.

  • ACCESSWIRE7 months ago

    Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on FGEN sign up now at www.wallstequities.com/registration. Pre-market, WallStEquities.com evaluates EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG), EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT), Fate Therapeutics Inc. (NASDAQ: FATE), and FibroGen Inc. (NASDAQ: FGEN).